KX2-391, the first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines. Phase 2.
choosing a selection results in a full page refresh
Product has been added to your wishlist.
You can view your wishlist by creating or login account.
Please create account through ##customer_email## email
